The AWGS 2025 Consensus: Implications for Sarcopenia Diagnosis and Screening | Market Intelligence

Description

List of Tables

In November 2025 the Asian Working Group for Sarcopenia issued its third consensus, and with it changed who counts as sarcopenic in Asia. The AWGS 2025 update extended diagnostic attention to the 50-to-64 age band and simplified the criteria that clinics are expected to apply. For Japan, where the professional community still works from guidelines published in 2018, the update creates an immediate divergence between international consensus and domestic practice, and a corresponding reset of the devices, protocols, and screening programs built around the older definitions.

The implications run in several directions at once. Diagnostic thresholds determine which patients enter care pathways, which cohorts qualify for epidemiological study, and which devices meet the technical requirements of the new criteria. Simplified case-finding lowers the barrier for primary-care and community screening, but it also shifts volume onto measurement infrastructure, grip dynamometry, gait-speed assessment, and bioimpedance or DXA body-composition analysis, that is unevenly distributed across Japanese care settings. Device vendors, screening operators, and clinic networks must now decide which systems to upgrade, replace, or certify against the revised consensus, while guideline bodies work through the domestic adoption process.

This report explains what changed, what it touches, and what remains open. It details the AWGS 2025 criteria point by point against AWGS 2019, EWGSOP2, and Japan's 2018 guidelines; maps the measurement-toolchain implications across BIA systems from Tanita, InBody, seca, Akern, and ImpediMed; DXA reference systems from Hologic and GE HealthCare; grip dynamometers from Takei and Jamar; and emerging ultrasound-based assessment from Canon Medical. It then examines the screening-program layer: municipal health checks, care-prevention programs under the LTCI system, and the reimbursement gap that currently leaves sarcopenia screening without a dedicated NHI code. International chapters compare how the US, EU5, and China handle sarcopenia recognition and device regulation.

The report is written for device manufacturers and distributors planning product and certification strategy, for screening-program operators and municipal health providers, and for pharma and nutrition companies whose trial eligibility criteria and market sizing depend on which definition prevails. It is designed to be usable as a reference document as the domestic adoption process unfolds.

Scope and Coverage

The report covers the AWGS 2025 consensus in full, its divergence from prior Asian, European, and Japanese criteria, and the implications for measurement devices, screening programs, and reimbursement across the US, EU5, Japan, and China. It addresses diagnostic and screening infrastructure rather than therapeutic pipelines.

Report Highlights

Point-by-point comparison of AWGS 2025 against AWGS 2019, EWGSOP2, and Japan's 2018 guidelines
Device-requirement reset across BIA, DXA, dynamometry, and ultrasound platforms
Vendor profiles for Tanita, InBody, Hologic, GE HealthCare, seca, and peers
Screening-program mechanics in municipal and LTCI care-prevention settings
Reimbursement status of sarcopenia screening and diagnosis in Japan
International regulatory and adoption comparison for diagnostic devices

Product Code: JPH-003

Table of Content

1. Executive Summary

2. The AWGS 2025 Consensus: Overview and Clinical Background

3. Epidemiology and Patient Population: US, EU5, Japan, and China

4. Current Treatment Landscape and Standard of Care

5. Pipeline and Development Activity

6. Regulatory Pathways: FDA, EMA, PMDA, and NMPA Considerations

7. Reimbursement and Pricing Analysis with a Focus on Japan's NHI System

8. Competitive Landscape and Key Companies

9. Unmet Needs and Commercial Opportunities in Japan

10. Appendix: Methodology and Sources

Companies Mentioned

Tanita (JP) - MC-780 and MC-980 segmental BIA analyzers used for AWGS appendicular-lean-mass assessment
InBody (KR) - InBody S10 and 770 BIA systems installed across Japanese hospitals
Hologic (US) - Horizon DXA systems for reference appendicular lean-mass measurement
GE HealthCare (US) - Lunar DXA line as the alternative reference standard
seca (DE) - mBCA medical BIA devices and chair scales for frail patients
Canon Medical (JP) - ultrasound-based muscle-assessment research platform
Takei Scientific Instruments (JP) - Smedley-type grip dynamometers used in Japanese cohorts
Jamar (US) - hydraulic grip dynamometer serving as the international protocol reference
Fukuda Denshi (JP) - medical-instrumentation distribution into Japanese clinics
Akern (IT) - bioimpedance vector-analysis systems used in sarcopenia research
ImpediMed (AU) - SOZO bioimpedance spectroscopy platform for clinical body composition
Omron Healthcare (JP) - consumer body-composition monitors bridging toward screening
Fresenius Medical Care (DE) - Body Composition Monitor BIA deployed in dialysis populations

Product Code: JPH-003

List of Tables

Table 1. AWGS consensus lineage: 2014, 2019, and 2025 editions and their structural differences
Table 2. Sarcopenia definition frameworks: AWGS, EWGSOP2, FNIH, and SDOC compared
Table 3. Japan's 2018 sarcopenia guidelines: issuing bodies, criteria, and current status
Table 4. AWGS 2025 consensus development process and participating societies
Table 5. Age-band extension to 50-64: populations newly in scope for diagnosis
Table 6. Case-finding instruments under AWGS 2025: SARC-F, SARC-CalF, and calf circumference
Table 7. Muscle-mass measurement requirements: BIA and DXA technical specifications
Table 8. Strength and physical-performance tests under the simplified criteria
Table 9. Screening populations by care setting: community, primary care, hospital, and care facility
Table 10. Current diagnostic pathway in Japanese practice and its divergence points
Table 11. Referral structures from case-finding to confirmatory assessment
Table 12. Role of the Kihon Checklist and frailty instruments adjacent to sarcopenia screening
Table 13. Integration of sarcopenia assessment into health-check (kenshin) programs
Table 14. Documentation and coding practice for sarcopenia in Japanese medical records
Table 15. Device and protocol development programs aligned to AWGS 2025 requirements
Table 16. BIA technology roadmap: segmental, multi-frequency, and vector-analysis approaches
Table 17. DXA technology roadmap: reference measurement and its access constraints
Table 18. Ultrasound-based muscle assessment: research programs and commercialization status
Table 19. Grip-dynamometry standardization programs and calibration requirements
Table 20. Gait-speed and chair-stand measurement protocols in screening settings
Table 21. PMDA device-classification considerations for body-composition analyzers
Table 22. FDA and EU MDR pathways for sarcopenia-relevant measurement devices
Table 23. NMPA registration pathway for BIA and DXA systems in China
Table 24. Clinical-validation expectations for devices used in consensus-based diagnosis
Table 25. Reimbursement status of sarcopenia screening under Japan's NHI system
Table 26. LTCI care-prevention funding streams applicable to screening programs
Table 27. Municipal health-program budgeting for frailty and sarcopenia screening
Table 28. International reimbursement comparison for body-composition assessment
Table 29. Pricing structures for BIA, DXA, and dynamometry equipment in Japan
Table 30. Tanita: MC-780 and MC-980 segmental BIA systems and clinical positioning
Table 31. InBody: S10 and 770 systems and Japanese hospital installations
Table 32. Hologic Horizon and GE HealthCare Lunar DXA lines in Japanese reference centers
Table 33. seca mBCA and chair-scale systems for frail-patient measurement
Table 34. Takei Smedley-type dynamometers and Jamar reference protocols
Table 35. Canon Medical ultrasound muscle-assessment research platform
Table 36. Akern, ImpediMed, and Omron: adjacent bioimpedance and consumer devices
Table 37. Fukuda Denshi distribution channel for medical instrumentation in Japan
Table 38. Fresenius Medical Care Body Composition Monitor in dialysis populations
Table 39. Vendor positioning map: devices against AWGS 2025 measurement requirements
Table 40. Distribution and service structures for measurement devices in Japan
Table 41. Screening-program operator landscape: municipal contractors and clinic chains
Table 42. Pharma and nutrition stakeholders using AWGS criteria in trial design
Table 43. Partnership structures between device makers and screening operators
Table 44. Certification and training programs for sarcopenia measurement staff
Table 45. Unmet needs: infrastructure gaps exposed by the AWGS 2025 update
Table 46. Guideline-adoption scenarios for Japanese societies and their implications
Table 47. Entry and expansion options for device vendors in the Japanese market
Table 48. Strategic options for screening operators under revised criteria
Table 49. Report methodology: consensus documents, device documentation, and interview base
Table 50. Glossary of criteria, devices, and program acronyms

List of Figures

Figure 1. AWGS consensus timeline: 2014, 2019, and 2025 editions
Figure 2. Sarcopenia definition landscape: AWGS, EWGSOP2, FNIH, and SDOC relationship map
Figure 3. Japan 2018 guideline structure and its divergence from AWGS 2025
Figure 4. Age-band extension schematic: populations entering diagnostic scope
Figure 5. Case-finding algorithm under AWGS 2025
Figure 6. Muscle-mass measurement decision flow: BIA versus DXA
Figure 7. Strength and performance test battery under the simplified criteria
Figure 8. Screening-population map by care setting
Figure 9. Current diagnostic pathway in Japanese practice
Figure 10. Referral flow from case-finding to confirmatory assessment
Figure 11. Kihon Checklist and frailty instruments adjacent to sarcopenia screening
Figure 12. Integration points for sarcopenia assessment in kenshin programs
Figure 13. Documentation and coding flow for sarcopenia in Japanese records
Figure 14. Device development roadmap aligned to AWGS 2025 requirements
Figure 15. BIA technology architecture: segmental, multi-frequency, and vector analysis
Figure 16. DXA reference-measurement access map in Japan
Figure 17. Ultrasound muscle-assessment development status diagram
Figure 18. Grip-dynamometry standardization and calibration workflow
Figure 19. Gait-speed and chair-stand protocol schematics
Figure 20. PMDA device-classification flow for body-composition analyzers
Figure 21. FDA and EU MDR pathway comparison for measurement devices
Figure 22. NMPA registration flow for BIA and DXA systems
Figure 23. Clinical-validation evidence ladder for diagnostic devices
Figure 24. NHI reimbursement decision points for sarcopenia screening
Figure 25. LTCI care-prevention funding flow to screening programs
Figure 26. Municipal budgeting process for frailty and sarcopenia programs
Figure 27. International reimbursement map for body-composition assessment
Figure 28. Equipment pricing structure map for measurement devices
Figure 29. Tanita segmental BIA product-line positioning
Figure 30. InBody hospital and clinic installation map
Figure 31. DXA installed-base structure in Japanese reference centers
Figure 32. seca and adjacent vendors in frail-patient measurement
Figure 33. Dynamometry landscape: Takei and Jamar protocol positions
Figure 34. Canon Medical ultrasound platform development schematic
Figure 35. Adjacent bioimpedance and consumer-device landscape
Figure 36. Fukuda Denshi distribution channel structure
Figure 37. Dialysis-population measurement: Fresenius BCM deployment model
Figure 38. Vendor positioning map against AWGS 2025 requirements
Figure 39. Device distribution and service network structure in Japan
Figure 40. Screening-operator landscape: municipal contractors and clinic chains
Figure 41. Pharma and nutrition trial-design usage of AWGS criteria
Figure 42. Device-maker and screening-operator partnership network
Figure 43. Certification and training program architecture
Figure 44. Infrastructure gap map exposed by the AWGS 2025 update
Figure 45. Guideline-adoption scenario tree for Japanese societies
Figure 46. Device-vendor entry and expansion options in Japan
Figure 47. Screening-operator strategic options under revised criteria
Figure 48. Report chapter logic and reading paths by user type
Figure 49. Methodology flow: consensus documents, device documentation, interviews
Figure 50. Data cut-off and update cadence schematic

The AWGS 2025 Consensus: Implications for Sarcopenia Diagnosis and Screening | Market Intelligence | US, EU5, Japan & China

Description

Table of Contents

List of Tables

Table of Content

1. Executive Summary

2. The AWGS 2025 Consensus: Overview and Clinical Background

3. Epidemiology and Patient Population: US, EU5, Japan, and China

4. Current Treatment Landscape and Standard of Care

5. Pipeline and Development Activity

6. Regulatory Pathways: FDA, EMA, PMDA, and NMPA Considerations

7. Reimbursement and Pricing Analysis with a Focus on Japan's NHI System

8. Competitive Landscape and Key Companies

9. Unmet Needs and Commercial Opportunities in Japan

10. Appendix: Methodology and Sources

Companies Mentioned

List of Tables

List of Figures